[Impacts of gestational weight gain on offspring weight and obesity: a 2-year follow up study]

Zhen-Zhen Liang1, Peng Zhu, Rong Gao

  • 1Department of Maternal and Child Health Care, Anhui Medical University, Hefei, China.

Insights

Excessive gestational weight gain increases children's obesity risk up to 12 months. This impact on offspring weight temporarily disappears during their second year of life.

Area of Science:

  • Obstetrics and Gynecology
  • Pediatrics
  • Public Health

Context:

  • Maternal health during pregnancy significantly influences offspring's long-term health outcomes.
  • Understanding the relationship between gestational weight gain and childhood obesity is crucial for preventative strategies.

Purpose:

  • To investigate the association between maternal gestational weight gain and offspring weight and obesity from birth to 24 months.
  • To identify critical periods where maternal weight gain impacts child development.

Summary:

  • This study analyzed data from 317 pregnant women and their offspring from birth to 24 months.
  • Excessive gestational weight gain was linked to a higher risk of childhood obesity at 6 and 9 months.
  • Gestational weight gain correlated with offspring weight Z-scores from birth to 12 months, with the effect diminishing by 18-24 months.

Impact:

  • Findings highlight the importance of monitoring and managing gestational weight gain to mitigate childhood obesity risks.
  • This research provides evidence for targeted interventions during pregnancy and early childhood to promote healthier growth trajectories.
Abstract

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...